Theravance Biopharma (TBPH) Non-Current Assets (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Non-Current Assets data on file, last reported at $54.7 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 71.72% year-over-year to $54.7 million in Q1 2026; TTM through Mar 2026 was $242.3 million, a 72.11% decrease from a year earlier, with the FY2025 full-year figure at $67.1 million, down 65.24% from the prior year.
• Non-Current Assets for Q1 2026 stood at $54.7 million, down from $67.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for TBPH reached as high as $277.2 million in Q1 2023 and fell as low as $54.7 million in Q1 2026.
• Historically, Non-Current Assets has averaged $191.3 million across 5 years, with a median of $239.6 million in 2024.
• Across the five-year window, Non-Current Assets jumped 573.66% in 2022 and slumped 75.39% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $253.9 million in 2022, then slipped by 2.16% to $248.5 million in 2023, then dropped by 22.28% to $193.1 million in 2024, then sank by 65.24% to $67.1 million in 2025, then declined by 18.52% to $54.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $54.7 million in Q1 2026, $67.1 million in Q4 2025, and $60.8 million in Q3 2025.